



04/23/2021

April 23, 2021

Dear COVID-19 Vaccine Providers:

As you may know, the Advisory Committee on Immunization Practices (ACIP) held a virtual emergency meeting today to discuss Johnson & Johnson (Janssen) COVID-19 vaccine.

Click [here](#) for the official FDA press announcement (*FDA and CDC Lift Recommended Pause on Johnson and Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review*).

In summary:

- Effective immediately, FDA and CDC **lift the recommended pause** on Janssen COVID-19 vaccine; use of the vaccine may resume.
- FDA issued an Emergency Use Agreement (EUA) **amendment** for the Janssen COVID-19 vaccine that includes warnings and precautions.
- Health care providers administering the vaccine and vaccine recipients or caregivers should review the [Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine \(Vaccination Providers\)](#) and [Fact Sheet for Recipients and Caregivers](#), which have been revised to include information about the risk of this syndrome, which has occurred in a very small number of people who have received the Janssen COVID-19 Vaccine.

Additional information/resources:

- [Fact Sheet for Healthcare Providers Administering Vaccine](#)
- [Fact Sheet for Recipients and Caregivers](#)
- [CDC Health Alert for Health Care Providers](#)
- [Johnson & Johnson Granting EUA Amendment \(April 23, 2021\)](#)

Additional information regarding Janssen orders, inventory, and clinical considerations will be updated incrementally and will be shared with COVID-19 providers as soon as it becomes available. It remains the recommendation of the Illinois Department of Public Health to talk to patients about the risks and benefits of any COVID-19 vaccine.

Thank you for your continued partnership and your tireless commitment to getting all eligible Illinoisans vaccinated against COVID-19.

For additional information regarding I-CARE, please visit: <https://dph.illinois.gov/topics-services/prevention-wellness/immunization/icare>